Curis, Inc. (NASDAQ:CRIS) Short Interest Update

Curis, Inc. (NASDAQ:CRIS) saw a significant drop in short interest in the month of December. As of December 15th, there was short interest totalling 44,900 shares, a drop of 39.4% from the November 30th total of 74,100 shares. Currently, 0.6% of the shares of the stock are sold short. Based on an average trading volume of 59,400 shares, the days-to-cover ratio is currently 0.8 days.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Curis stock. Point72 Asset Management L.P. boosted its holdings in shares of Curis, Inc. (NASDAQ:CRIS) by 795.5% in the second quarter, according to its most recent filing with the SEC. The firm owned 108,356 shares of the biotechnology company’s stock after acquiring an additional 96,256 shares during the period. Point72 Asset Management L.P. owned 1.84% of Curis worth $748,000 as of its most recent filing with the SEC. 29.97% of the stock is owned by hedge funds and other institutional investors.

Curis Trading Down 0.9 %

Shares of CRIS stock opened at $3.14 on Friday. The firm has a market capitalization of $26.59 million, a price-to-earnings ratio of -0.40 and a beta of 3.34. The firm’s 50 day moving average is $4.15 and its 200-day moving average is $5.32. Curis has a 1 year low of $3.05 and a 1 year high of $17.49.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and set a $20.00 price target on shares of Curis in a report on Tuesday, December 10th.

About Curis

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.